AngioDynamics holder Kevin Kotler reports 5.9% stake
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026. He holds sole voting and dispositive power over these shares and reports the stake as passive, not for influencing control.
The filing notes that 313,495 shares are owned in his individual capacity, while the remainder is held in accounts he manages. He also formally disclaims beneficial ownership beyond his pecuniary interest in the reported securities.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in AngioDynamics (ANGO) does Kevin Kotler report on this Schedule 13G?
Is Kevin Kotler’s AngioDynamics (ANGO) position reported as passive or activist?
Does Kevin Kotler fully acknowledge beneficial ownership of all reported AngioDynamics (ANGO) shares?
AI-generated analysis. How Rhea-AI works. Not financial advice.